🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

57,13 USD

Máx. histórico

149,13

4125 días

Caída desde máximo

-61,69%

Rango 52 semanas

49,26 – 70,98

Variación hoy

+2,64%

Cierre anterior

55,66

Rango de hoy

55,67 – 57,51

Volumen hoy

2.843.464

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 3 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/10/2022 87,42 89,04 87,12 88,07 +0,71% 2,20% 1.222.200
10/10/2022 87,84 88,81 87,39 87,45 -0,79% 1,62% 967.900
07/10/2022 91,16 91,16 87,63 88,15 -3,64% 3,87% 1.076.000
06/10/2022 89,25 92,06 88,75 91,48 +2,18% 3,71% 1.539.200
05/10/2022 87,89 89,82 87,40 89,53 +1,84% 2,75% 1.276.500
04/10/2022 87,18 88,08 85,76 87,91 +1,40% 2,66% 1.439.600
03/10/2022 85,64 87,43 84,57 86,70 +2,28% 3,34% 931.700
30/09/2022 84,99 86,75 84,51 84,77 -0,34% 2,64% 1.437.100
29/09/2022 85,65 85,79 84,27 85,06 -0,91% 1,77% 788.000
28/09/2022 84,37 86,20 83,47 85,84 +2,88% 3,24% 1.358.900
27/09/2022 82,87 84,43 82,54 83,44 +1,56% 2,28% 1.265.700
26/09/2022 84,20 84,48 81,66 82,16 -3,16% 3,35% 1.401.700
23/09/2022 84,29 84,93 83,38 84,84 -0,09% 1,84% 1.023.500
22/09/2022 84,45 85,24 83,71 84,92 -0,23% 1,81% 868.200
21/09/2022 86,99 87,37 85,01 85,12 -2,12% 2,71% 460.000
20/09/2022 86,82 87,68 86,17 86,96 -0,84% 1,74% 472.000
19/09/2022 87,92 88,02 86,83 87,70 -0,58% 1,35% 694.600
16/09/2022 87,25 88,31 86,70 88,21 +0,14% 1,85% 1.245.500
15/09/2022 86,63 88,21 85,73 88,09 +1,42% 2,86% 855.500
14/09/2022 86,78 87,14 85,68 86,86 +0,37% 1,68% 964.000
13/09/2022 89,51 89,51 86,25 86,54 -4,10% 3,64% 1.391.400
12/09/2022 90,00 90,73 88,31 90,24 -2,89% 2,69% 1.442.500
09/09/2022 92,29 93,23 91,82 92,93 -0,09% 1,53% 721.900
08/09/2022 91,26 93,05 90,99 93,01 +1,97% 2,26% 964.300
07/09/2022 88,96 91,64 88,70 91,21 +2,66% 3,30% 853.100
06/09/2022 89,64 89,92 88,29 88,85 -0,88% 1,82% 834.300
02/09/2022 91,16 91,40 89,21 89,64 -1,35% 2,40% 644.600
01/09/2022 89,17 90,90 88,78 90,87 +1,87% 2,38% 1.106.500
31/08/2022 90,46 91,14 89,05 89,20 -1,10% 2,31% 1.457.600
30/08/2022 90,30 90,92 89,28 90,19 -0,15% 1,82% 912.500